Page 1881 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 108 Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses 1668.e5

188. Marrack P, Mitchell T, Bender J, et al: T-cell survival. Immunol Rev 211. Hill GR, Ferrara JL: The primacy of the gastrointestinal tract as a
165:279, 1998. target organ of acute graft-versus-host disease: rationale for the use
189. Hildeman DA, Zhu Y, Mitchell TC, et al: Activated T cell death in of cytokine shields in allogeneic bone marrow transplantation. Blood
vivo mediated by proapoptotic BCL-2 family member bim. Immunity 95(9):2754–2759, 2000.
16:759, 2002. 212. Nikolic B, Lee S, Bronson RT, et al: Th1 and Th2 mediate acute
190. Hildeman DA, Zhu Y, Mitchell TC, et al: Molecular mechanisms of graft-versus-host disease, each with distinct end-organ targets. J Clin
activated T cell death in vivo. Curr Opin Immunol 14:354, 2002. Invest 105(9):1289–1298, 2000.
191. Drobyski WR, Komorowski R, Logan B, et al: Role of the passive 213. Burman AC, Banovic T, Kuns RD, et al: IFNgamma differentially
apoptotic pathway in graft-versus-host disease. J Immunol 169:1626, controls the development of idiopathic pneumonia syndrome and
2002. GVHD of the gastrointestinal tract. Blood 110(3):1064–1072, 2007.
192. Drobyski WR, Gendelman M: Regulation of alloresponses after bone 214. Nikolic B, Lee S, Bronson R, et al: Th1 and Th2 mediate acute graft-
marrow transplantation using donor T cells expressing a thymidine versus-host disease, each with distinct end-organ targets. J Clin Invest
kinase suicide gene. Leuk Lymphoma 43:2011, 2002. 105:1289, 2000.
193. Drobyski WR, Klein J, Flomenberg N, et al: Superior survival associ- 215. Carlson MJ, West ML, Coghill JM, et al: In vitro-differentiated TH17
ated with transplantation of matched unrelated versus one-antigen- cells mediate lethal acute graft-versus-host disease with severe cutaneous
mismatched unrelated or highly human leukocyte antigen-disparate and pulmonary pathologic manifestations. Blood 113(6):1365–1374,
haploidentical family donor marrow grafts for the treatment of hema- 2009.
tologic malignancies: establishing a treatment algorithm for recipients 216. Kappel LW, Goldberg GL, King CG, et al: IL-17 contributes to CD4-
of alternative donor grafts. Blood 99:806, 2002. mediated graft-versus-host disease. Blood 113(4):945–952, 2009.
194. Bonini C, Bordignon C: Potential and limitations of HSV-TK-trans- 217. Reichenbach DK, Schwarze V, Matta BM, et al: The IL-33/ST2
duced donor peripheral blood lymphocytes after allo-BMT. Hematol axis augments effector T-cell responses during acute GVHD. Blood
Cell Ther 39:273, 1997. 125(20):3183–3192, 2015.
195. Chen BJ, Cui X, Liu C, et al: Prevention of graft-versus-host disease 218. Fulton LM, Carlson MJ, Coghill JM, et al: Attenuation of acute
while preserving graft-versus-leukemia effect after selective depletion graft-versus-host disease in the absence of the transcription factor
of host-reactive T cells by photodynamic cell purging process. Blood RORgammat. J Immunol 189(4):1765–1772, 2012.
99:3083, 2002. 219. Markey KA, MacDonald KP, Hill GR: The biology of graft-versus-
196. Byersdorfer CA, Tkachev V, Opipari AW, et al: Effector T cells require host disease: experimental systems instructing clinical practice. Blood
fatty acid metabolism during murine graft-versus-host disease. Blood 124(3):354–362, 2014.
122(18):3230, 2013. 220. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, et al: Leukocyte
197. Gatza E, Wahl DR, Opipari AW, et al: Manipulating the bioenergetics migration and graft-versus-host disease. Blood 105:4191, 2005.
of alloreactive T cells causes their selective apoptosis and arrests graft- 221. Cyster JG: Chemokines, sphingosine-1-phosphate, and cell migration
versus-host disease. Sci Transl Med 3(67):67ra8, 2011. in secondary lymphoid organs. Annu Rev Immunol 23:127, 2005.
198. Liu J, Farmer JD, Jr, Lane WS, et al: Calcineurin is a common target 222. Serody JS, Burkett SE, Panoskaltsis-Mortari A, et al: T-lymphocyte
of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell production of macrophage inflammatory protein-1alpha is critical to
+
66(4):807–815, 1991. the recruitment of CD8( ) T cells to the liver, lung, and spleen during
199. Blazar BR, Taylor PA, Snover DC, et al: Murine recipients of fully graft-versus-host disease. Blood 96:2973, 2000.
mismatched donor marrow are protected from lethal graft-versus-host 223. Mapara MY, Leng C, Kim YM, et al: Expression of chemokines in
disease by the in vivo administration of rapamycin but develop an GVHD target organs is influenced by conditioning and genetic factors
autoimmune-like syndrome. J Immunol 151(10):5726–5741, 1993. and amplified by GVHR. Biol Blood Marrow Transplant 12:623,
200. Pai CC, Chen M, Mirsoian A, et al: Treatment of chronic graft-versus- 2006.
host disease with bortezomib. Blood 124(10):1677–1688, 2014. 224. Duffner U, Lu B, Hildebrandt GC, et al: Role of CXCR3-induced
201. Mathewson N, Toubai T, Kapeles S, et al: Neddylation plays an impor- donor T-cell migration in acute GVHD. Exp Hematol 31:897, 2003.
tant role in the regulation of murine and human dendritic cell function. 225. Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, et al: Differential
Blood 122(12):2062–2073, 2013. roles for CCR5 expression on donor T cells during graft-versus-host
202. Sun Y, Wang Y, Toubai T, et al: BET bromodomain inhibition suppresses disease based on pretransplant conditioning. J Immunol 173:845, 2004.
graft-versus-host disease after allogeneic bone marrow transplantation 226. Murai M, Yoneyama H, Harada A, et al: Active participation of
+
+
in mice. Blood 125(17):2724–2728, 2015. CCR5( )CD8( ) T lymphocytes in the pathogenesis of liver injury in
203. Sun Y, Oravecz-Wilson K, Mathewson N, et al: Mature T cell responses graft-versus-host disease. J Clin Invest 104:49, 1999.
are controlled by microRNA-142. J Clin Invest 125(7):2825–2840, 227. Wysocki C, Burkett S, Chwastiak K, et al: CCR5 expression on
+
+
2015. CD4 CD25 regulatory T cells plays a critical role in their ability to
204. Ranganathan P, Heaphy CE, Costinean S, et al: Regulation of acute prevent GVHD. Blood 102:#517, 2003.
graft-versus-host disease by microRNA-155. Blood 119(20):4786–4797, 228. Reshef R, Luger SM, Hexner EO, et al: Blockade of lymphocyte chemo-
2012. taxis in visceral graft-versus-host disease. N Engl J Med 367(2):135–145,
205. Ayash LJ, Clarke M, Silver SM, et al: Double dose-intensive chemo- 2012.
therapy with autologous stem cell support for relapsed and refractory 229. Waldman E, Lu SX, Hubbard VM, et al: Absence of beta7 integrin
testicular cancer: the University of Michigan experience and literature results in less graft-versus-host disease because of decreased homing of
review. Bone Marrow Transplant 27:939, 2001. alloreactive T cells to intestine. Blood 107:1703, 2006.
206. Ferrara JLM: The cytokine storm of acute graft-versus host disease. 230. Welniak LA, Kuprash DV, Tumanov AV, et al: Peyer’s patches are not
Haematol Rev 8:27, 1994. required for acute graft-versus-host disease after myeloablative condi-
207. Reddy P: Pathophysiology of acute graft-versus-host disease. Hematol tioning and murine allogeneic bone marrow transplantation. Blood
Oncol 21:149, 2003. 107:410, 2006.
208. Chen X, Das R, Komorowski R, et al: Blockade of interleukin-6 231. Kim YM, Sachs T, Asavaroengchai W, et al: Graft-versus-host disease
signaling augments regulatory T-cell reconstitution and attenuates the can be separated from graft-versus-lymphoma effects by control of
severity of graft-versus-host disease. Blood 114:891, 2009. lymphocyte trafficking with FTY720. J Clin Invest 111:659, 2003.
209. McDonald-Hyman C, Turka LA, Blazar BR: Advances and challenges 232. Lee RS, Kuhr CS, Sale GE, et al: FTY720 does not abrogate acute
in immunotherapy for solid organ and hematopoietic stem cell trans- graft-versus-host disease in the dog leukocyte antigen-nonidentical
plantation. Sci Transl Med 7(280):280rv2, 2015. unrelated canine model. Transplantation 76:1155, 2003.
210. Teshima T, Maeda Y, Ozaki K: Regulatory T cells and IL-17-pro- 233. Sallusto F, Mackay CR, Lanzavecchia A: The role of chemokine recep-
ducing cells in graft-versus-host disease. Immunotherapy 3(7):833–852, tors in primary, effector, and memory immune responses. Annu Rev
2011. Immunol 18:593, 2000.